Key facts
- Syntis Bio’s last known valuation is $67.0M (Jun 2025).
- It has raised $48.4M across 3 recorded rounds; the latest was Early Stage VC ($25.0M) in Jun 2025.
- Notable investors include National Institutes of Health, Sky9 Capital, Safar Partners, Woori Venture Partners, BOLD Capital Partners — 12 tracked in total.
- Syntis Bio has filed 4 Form Ds with the SEC since 2022, most recently Jul 2025 ($25.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Syntis Bio
Funding rounds
3 roundsAbout Syntis Bio
Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. The company's drug uses formulations for oral therapies that target specific tissues to leverage the small intestine's biology for metabolic and rare disease treatments through a daily nutrient-blocking pill using transient polymer coatings and gut-stable enzyme therapies, enabling researchers to treat patients within a broader disease category and with an effective options that mimic surgical benefits and reduce dietary restrictions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 17
- Website
- syntis.bio/
- Ownership
- Privately Held (backing)
Syntis Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syntis Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syntis Bio in its N-PORT filings yet. We sweep new filings monthly.